CN117137891A - 一种原儿茶醛与镍铁改性的UiO-66-NH2的杂化材料及其制备方法和应用 - Google Patents
一种原儿茶醛与镍铁改性的UiO-66-NH2的杂化材料及其制备方法和应用 Download PDFInfo
- Publication number
- CN117137891A CN117137891A CN202311088924.7A CN202311088924A CN117137891A CN 117137891 A CN117137891 A CN 117137891A CN 202311088924 A CN202311088924 A CN 202311088924A CN 117137891 A CN117137891 A CN 117137891A
- Authority
- CN
- China
- Prior art keywords
- uio
- ferronickel
- protocatechuic aldehyde
- nickel
- hybrid material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 title claims abstract description 128
- 239000000463 material Substances 0.000 title claims abstract description 72
- 229960003371 protocatechualdehyde Drugs 0.000 title claims abstract description 64
- 229910000863 Ferronickel Inorganic materials 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title claims description 21
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 claims abstract description 20
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 18
- GPNNOCMCNFXRAO-UHFFFAOYSA-N 2-aminoterephthalic acid Chemical compound NC1=CC(C(O)=O)=CC=C1C(O)=O GPNNOCMCNFXRAO-UHFFFAOYSA-N 0.000 claims abstract description 10
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 claims abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 22
- UGKDIUIOSMUOAW-UHFFFAOYSA-N iron nickel Chemical compound [Fe].[Ni] UGKDIUIOSMUOAW-UHFFFAOYSA-N 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 10
- 238000001354 calcination Methods 0.000 claims description 9
- 150000002815 nickel Chemical class 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- DUNKXUFBGCUVQW-UHFFFAOYSA-J zirconium tetrachloride Chemical compound Cl[Zr](Cl)(Cl)Cl DUNKXUFBGCUVQW-UHFFFAOYSA-J 0.000 claims description 9
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 8
- 238000005470 impregnation Methods 0.000 claims description 7
- 150000002505 iron Chemical class 0.000 claims description 7
- KBJMLQFLOWQJNF-UHFFFAOYSA-N nickel(ii) nitrate Chemical compound [Ni+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O KBJMLQFLOWQJNF-UHFFFAOYSA-N 0.000 claims description 7
- 238000001816 cooling Methods 0.000 claims description 6
- 239000008367 deionised water Substances 0.000 claims description 6
- 229910021641 deionized water Inorganic materials 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- VCJMYUPGQJHHFU-UHFFFAOYSA-N iron(3+);trinitrate Chemical compound [Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O VCJMYUPGQJHHFU-UHFFFAOYSA-N 0.000 claims description 6
- 239000012265 solid product Substances 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 claims description 5
- MCDLETWIOVSGJT-UHFFFAOYSA-N acetic acid;iron Chemical compound [Fe].CC(O)=O.CC(O)=O MCDLETWIOVSGJT-UHFFFAOYSA-N 0.000 claims description 5
- 229960002089 ferrous chloride Drugs 0.000 claims description 5
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 claims description 5
- RUTXIHLAWFEWGM-UHFFFAOYSA-H iron(3+) sulfate Chemical compound [Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RUTXIHLAWFEWGM-UHFFFAOYSA-H 0.000 claims description 5
- 229910000360 iron(III) sulfate Inorganic materials 0.000 claims description 5
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 claims description 5
- 239000003054 catalyst Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 238000001027 hydrothermal synthesis Methods 0.000 claims description 4
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims description 3
- 229910021578 Iron(III) chloride Inorganic materials 0.000 claims description 3
- 229910002651 NO3 Inorganic materials 0.000 claims description 3
- VEQPNABPJHWNSG-UHFFFAOYSA-N Nickel(2+) Chemical compound [Ni+2] VEQPNABPJHWNSG-UHFFFAOYSA-N 0.000 claims description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 3
- 238000007598 dipping method Methods 0.000 claims description 3
- 235000003891 ferrous sulphate Nutrition 0.000 claims description 3
- 239000011790 ferrous sulphate Substances 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- -1 iron ions Chemical class 0.000 claims description 3
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 3
- PVFSDGKDKFSOTB-UHFFFAOYSA-K iron(3+);triacetate Chemical compound [Fe+3].CC([O-])=O.CC([O-])=O.CC([O-])=O PVFSDGKDKFSOTB-UHFFFAOYSA-K 0.000 claims description 3
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 3
- 229910001453 nickel ion Inorganic materials 0.000 claims description 3
- 238000000643 oven drying Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 230000000630 rising effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 7
- 241000894006 Bacteria Species 0.000 abstract description 6
- 206010041925 Staphylococcal infections Diseases 0.000 abstract description 6
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 6
- 230000003013 cytotoxicity Effects 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 6
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 230000004048 modification Effects 0.000 abstract description 4
- 238000012986 modification Methods 0.000 abstract description 4
- 230000003115 biocidal effect Effects 0.000 abstract description 3
- 208000015181 infectious disease Diseases 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 12
- 239000012621 metal-organic framework Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000001179 sorption measurement Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 5
- KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 229910021645 metal ion Inorganic materials 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000944 Soxhlet extraction Methods 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- 229960001931 ampicillin sodium Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 201000010897 colon adenocarcinoma Diseases 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000013110 organic ligand Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 description 1
- HBQRAUJPLJWVDR-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O.OC1=CC=C(C=O)C=C1O HBQRAUJPLJWVDR-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
- C08G83/008—Supramolecular polymers
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/08—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing solids as carriers or diluents
- A01N25/10—Macromolecular compounds
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N35/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having two bonds to hetero atoms with at the most one bond to halogen, e.g. aldehyde radical
- A01N35/04—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having two bonds to hetero atoms with at the most one bond to halogen, e.g. aldehyde radical containing aldehyde or keto groups, or thio analogues thereof, directly attached to an aromatic ring system, e.g. acetophenone; Derivatives thereof, e.g. acetals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N55/00—Biocides, pest repellants or attractants, or plant growth regulators, containing organic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen and sulfur
- A01N55/02—Biocides, pest repellants or attractants, or plant growth regulators, containing organic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen and sulfur containing metal atoms
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/223—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material containing metals, e.g. organo-metallic compounds, coordination complexes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/3085—Chemical treatments not covered by groups B01J20/3007 - B01J20/3078
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/22—Organic complexes
- B01J31/2204—Organic complexes the ligands containing oxygen or sulfur as complexing atoms
- B01J31/2208—Oxygen, e.g. acetylacetonates
- B01J31/2226—Anionic ligands, i.e. the overall ligand carries at least one formal negative charge
- B01J31/2243—At least one oxygen and one nitrogen atom present as complexing atoms in an at least bidentate or bridging ligand
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/40—Complexes comprising metals of Group IV (IVA or IVB) as the central metal
- B01J2531/48—Zirconium
Abstract
本发明公开一种原儿茶醛与镍铁改性的UiO‑66‑NH2的杂化材料及其制备方法和应用，将氯化锆、2‑氨基对苯二甲酸与对苯二甲酸分散至N,N‑二甲基甲酰胺DMF中制得UiO‑66‑NH2，再进行原儿茶醛与镍铁改性，得到所述杂化材料。本发明所得杂化材料在抗菌性能方面具有极大提升，具有对MRSA在内的耐药菌的抑制作用，能够减少感染风险与抗生素使用。本发明杂化材料使原儿茶醛能够缓慢释放，并且极大地改善了其化学稳定性，同时提高了其长时间持续抗菌的能力。本发明杂化材料产生较低的细胞毒性，具有良好的生物相容性和医学使用前景。
Description
技术领域
本发明涉及纳米药物技术领域，具体涉及一种原儿茶醛与镍铁改性的UiO-66-NH2的杂化材料及其制备方法和应用，尤其是涉及一种金属有机框架原儿茶醛与镍铁改性的UiO-66-NH2的杂化材料的制备方法及抗菌应用。
背景技术
细菌污染是食品、医药等众多领域最具挑战性的问题之一，威胁着全球数百万人的生命。抗生素耐药性是其中最大的健康挑战之一，也是对公共卫生的全球性挑战。鉴于现有的抗生素耐药性及其快速产生新耐药表型的能力，迫切需要开发和设计一种或对人类有效且安全的新型抗菌剂。
原儿茶醛，学名为3，4-二羟基苯甲醛(3，4-dihydroxybenzaldehyde)，是丹参水溶性成分丹酚酸B降解的主要产物之一，常作为质量检测指标控制丹参相关制剂的质量，具有优异的抗菌活性和生物相容性。
金属有机框架(MOFs)是一类新型的无机-有机杂化结晶多孔材料，其中金属节点和有机配体通过配位键连接在一起。金属离子或金属离子簇和有机分子(称为连接体)是MOF的两个主要成分，金属离子中心和有机配体之间通过配位键或共价键连接，形成无限网络结构。金属离子和配体具有丰富的几何形状和成键特性。因此，MOFs的物理化学特性可以人为设计和优化，以适应不同的应用场景。但是纯MOFs存在抗菌性不足等缺点，因此迫切需要一种改性和复合方法来弥补这一缺点。
发明内容
本发明的第一个目的是针对现有技术的不足，提供一种具有抗菌活性和降低耐药率的镍铁改性的UiO-66-NH2和原儿茶醛杂化材料的制备方法，采用的技术方案为：
步骤(1)、UiO-66-NH2的制备
将氯化锆、2-氨基对苯二甲酸与对苯二甲酸分散至N,N-二甲基甲酰胺DMF中，搅拌下加入去离子水，加热反应一段时间；冷却至室温后，离心收集固体产物，置于无水乙醇中一段时间，取出烘干后即得UiO-66-NH2；所述氯化锆、2-氨基对苯二甲酸与对苯二甲酸的质量比为5：1：(2.5～2.7)；
步骤(2)、镍铁改性的UiO-66-NH2杂化材料的制备
将铁盐、镍盐溶于无水甲醇中，加入步骤(1)所得UiO-66-NH2，分散均匀，常温搅拌12～24h，然后在氮气或氩气等惰性气氛中煅烧，得到所述镍铁改性的UiO-66-NH2杂化材料；UiO-66-NH2、铁盐中的铁离子、镍盐中的镍离子与无水甲醇的摩尔比为1：(1.5～2)：(1.5～2)：(3000～4000)；
步骤(3)、原儿茶醛与镍铁改性的UiO-66-NH2的杂化材料的制备
将原儿茶醛分散至水中，加入步骤(2)所得镍铁改性的UiO-66-NH2的杂化材料进行浸渍，静置后洗涤干燥得到所述原儿茶醛与镍铁改性UiO-66-NH2的杂化材料。
作为优选，步骤(1)中加热时间为22～24h，加热温度为118～120℃。
作为优选，步骤(1)中置于乙醇中22～24h。
作为优选，步骤(2)中水热反应的时间为24h，水热反应的温度为120℃。
作为优选，步骤(2)中铁盐选自二价铁盐、三价铁盐中一种或两种；所述二价铁盐为氯化亚铁、硝酸亚铁、硫酸亚铁、醋酸亚铁中任意一种或几种；所述三价铁盐为氯化铁、硝酸铁、硫酸铁、醋酸铁中一种或几种。
作为优选，步骤(2)中镍盐选自硝酸镍、氯化镍中一种或两种。
作为优选，步骤(2)中煅烧温度为600～900℃，升温速率为1～10℃/min，煅烧时间为4～16h。
作为优选，步骤(3)中浸渍的时间为4～40h。
本发明的第二个目的是提供一种原儿茶醛与镍铁改性的UiO-66-NH2的杂化材料，采用上述方法制备得到。
本发明的第三个目的是提供上述杂化材料作为抗菌材料或催化剂的应用。
与现有技术相比，本发明的有益效果在于：
一、本发明采用单一溶剂液相还原法制备了原儿茶醛与镍铁改性的UiO-66-NH2的杂化材料，本发明制备的镍铁改性后的UiO-66-NH2增强了原本的金属有机框架材料的吸附性能和抗菌活性，同时保持了原有的生物相容性。其中包含镍铁改性的UiO-66-NH2和原儿茶醛两种主要成分，在抗菌过程中起到协同作用，极大地提高了材料的抗菌性能，使之成为一种有效的纳米协同抗菌剂；原儿茶醛与镍铁改性的UiO-66-NH2的杂化材料在实验中发现具有对MRSA在内的耐药菌的抑制作用，能够减少感染风险与抗生素使用。
二、本发明制备的原儿茶醛与镍铁改性的UiO-66-NH2杂化材料，通过加入镍铁获得了更强的吸附性能和催化效率，可用作催化剂。
三、通过将原儿茶醛负载在镍铁改性的UiO-66-NH2金属有机框架材料中使原儿茶醛能够缓慢释放，并且极大地改善了其化学稳定性，同时提高了其长时间持续抗菌的能力。
四、原儿茶醛与镍铁改性的UiO-66-NH2杂化材料产生较低的细胞毒性，具有良好的生物相容性，具有良好的医学使用前景。
附图说明
图1为各材料抑制MRSA的平板计数图，其中A为镍铁改性的UiO-66-NH2，B为原儿茶醛，C为原儿茶醛和镍铁改性的UiO-66-NH2杂化材料。
图2为实施例1制备的原儿茶醛与镍铁改性的UiO-66-NH2细胞毒性图。
图3为实施例1制备的UiO-66-NH2的傅里叶红外光谱分析(FT-IR图)。
具体实施方式
以下结合附图实施例对本发明作进一步详细描述。
第一方面，本发明提供一种原儿茶醛与镍铁改性的UIO-66-NH2的杂化材料的制备方法，包括如下步骤：
步骤(1)、UiO-66-NH2的制备
将氯化锆、2-氨基对苯二甲酸与对苯二甲酸分散至N,N-二甲基甲酰胺DMF中，搅拌下加入去离子水，加热至118～120℃反应22～24h；冷却至室温后，离心收集固体产物，置于无水乙醇中22～24h，取出烘干后即得UiO-66-NH2；其中，氯化锆、2-氨基对苯二甲酸与对苯二甲酸的质量比为5：1：(2.5～2.7)；
步骤(2)、镍铁改性的UiO-66-NH2杂化材料的制备
将铁盐、镍盐溶于无水甲醇中，加入步骤(1)所得UiO-66-NH2，分散均匀，常温搅拌12～24h，然后在氮气或氩气等惰性气氛中，600-900℃煅烧4～16h，得到所述镍铁改性的UiO-66-NH2杂化材料；UiO-66-NH2、铁盐中的铁离子、镍盐中的镍离子与无水甲醇的摩尔比为1：(1.5～2)：(1.5～2)：(3000～4000)；所述铁盐选自二价铁盐、三价铁盐中一种或几种；所述二价铁盐为氯化亚铁、硝酸亚铁、硫酸亚铁、醋酸亚铁中的一种或几种；所述三价铁盐为氯化铁、硝酸铁、硫酸铁、醋酸铁中一种或几种；所述镍盐为硝酸镍、氯化镍中的一种或两种；
步骤(3)、原儿茶醛与镍铁改性的UiO-66-NH2的杂化材料的制备
将原儿茶醛分散至水中，加入步骤(2)所得镍铁改性的UiO-66-NH2的杂化材料进行浸渍4～40h，静置后洗涤干燥得到所述原儿茶醛与镍铁改性UiO-66-NH2的杂化材料。
第二方面，本发明提供一种原儿茶醛与镍铁改性的UIO-66-NH2的杂化材料，采用上述方法制备得到。
第三方面，本发明提供上述杂化材料作为抗菌材料或催化剂的应用。
以下结合若干较佳实施例对本发明的技术方案作进一步的解释说明，但其中的实验条件和设定参数不应视为对本发明基本技术方案的局限，并且本发明的保护范围不限于下述的实施例。
实施例1：制备原儿茶醛和镍铁改性的UiO-66-NH2杂化材料
(1)UiO-66-NH2的制备
首先称取氯化锆(1.25mmol)、2-氨基对苯二甲酸(0.44mmol)和对苯二甲酸(1.28mmol)分散到100mLN,N-二甲基甲酰胺中，在剧烈搅拌下滴加150μL去离子水，搅拌并分散完全，之后转入不锈钢反应釜中，在120℃温度条件下恒温加热箱中反应24h。冷却至室温后，离心收集固体产物，用无水乙醇索氏提取法洗涤置换高沸点有机溶剂N,N-二甲基甲酰胺24h，80℃真空干燥箱烘干12h，得粉末状产物，即为UiO-66-NH2；所得UiO-66-NH2的傅里叶红外光谱分析(FT-IR图)见图3。
(2)镍铁改性的UiO-66-NH2(Ni@Fe/UiO-66-NH2)的制备
将硫酸铁、氯化镍溶于无水甲醇中，加入步骤(1)所得UiO-66-NH2，分散均匀，常温搅拌12～24h，然后在氮气中600℃煅烧16h，得到所述镍铁改性的UiO-66-NH2杂化材料；UiO-66-NH2、Fe3+ (硫酸铁)、Ni2+ (氯化镍)与无水甲醇的摩尔比为1：2：3：4000。
(3)原儿茶醛和镍铁改性的UiO-66-NH2的杂化材料(DIH/Ni@Fe/UiO-66-NH2)的制备
镍将原儿茶醛分散与水中，加入镍铁改性的UiO-66-NH2的杂化材料进行浸渍反应4-40小时，静置2-4小时，洗涤，80℃干燥得到原儿茶醛和镍铁改性的UiO-66-NH2的杂化材料(DIH/Ni@Fe/UiO-66-NH2)。
实施例2：制备原儿茶醛和镍铁改性的UiO-66-NH2杂化材料
(1)UiO-66-NH2的制备
首先称取氯化锆(1.25mmol)、2-氨基对苯二甲酸(0.44mmol)和对苯二甲酸(1.28mmol)分散到100mLN,N-二甲基甲酰胺中，在剧烈搅拌下滴加150μL去离子水，搅拌并分散完全，之后转入不锈钢反应釜中，在120℃温度条件下恒温加热箱中反应24h。冷却至室温后，离心收集固体产物，用无水乙醇索氏提取法洗涤置换高沸点有机溶剂N,N-二甲基甲酰胺24h，80℃真空干燥箱烘干12h，得粉末状产物，即为UiO-66-NH2。
(2)镍铁改性的UiO-66-NH2的制备
将醋酸亚铁、硝酸镍溶于无水甲醇中，加入步骤(1)所得UiO-66-NH2，分散均匀，常温搅拌12～24h，然后在氮气中600℃煅烧16h，得到所述镍铁改性的UiO-66-NH2杂化材料；UiO-66-NH2、Fe2+ (醋酸亚铁)、Ni2+ (硝酸镍)与无水甲醇的摩尔比为1：2：3：4000。
(3)原儿茶醛和镍铁改性的UiO-66-NH2的杂化材料的制备
采用浸渍法制备原儿茶醛和镍铁改性的UiO-66-NH2的杂化材料。将原儿茶醛分散与水中，加入镍铁改性的UiO-66-NH2的杂化材料进行浸渍反应4小时，静置4小时，洗涤，80℃干燥得到原儿茶醛和镍铁改性的UiO-66-NH2的杂化材料。
实施例3：制备原儿茶醛和镍铁改性的UiO-66-NH2杂化材料
(1)UiO-66-NH2的制备
首先称取氯化锆(1.25mmol)、2-氨基对苯二甲酸(0.44mmol)和对苯二甲酸(1.28mmol)分散到100mLN,N-二甲基甲酰胺中，在剧烈搅拌下滴加150μL去离子水，搅拌并分散完全，之后转入不锈钢反应釜中，在120℃温度条件下恒温加热箱中反应24h。冷却至室温后，离心收集固体产物，用无水乙醇索氏提取法洗涤置换高沸点有机溶剂N,N-二甲基甲酰胺24h，80℃真空干燥箱烘干12h，得粉末状产物，即为UiO-66-NH2。
(2)镍铁改性的UiO-66-NH2的制备
将氯化亚铁、硝酸镍溶于无水甲醇中，加入步骤(1)所得UiO-66-NH2，分散均匀，常温搅拌12～24h，然后在氩气中700℃煅烧10h，得到所述镍铁改性的UiO-66-NH2杂化材料；UiO-66-NH2、Fe2+ (氯化亚铁)、Ni2+ (硝酸镍)与无水甲醇的摩尔比为1：1.8：1.7：3800。
(3)原儿茶醛和镍铁改性的UiO-66-NH2的杂化材料的制备
采用浸渍法制备原儿茶醛和镍铁改性的UiO-66-NH2的杂化材料。将原儿茶醛分散与水中，加入镍铁改性的UiO-66-NH2的杂化材料进行浸渍反应40小时，静置2小时，洗涤，80℃干燥得到原儿茶醛和镍铁改性的UiO-66-NH2的杂化材料。
测试例1：表征及抗菌试验
本测试例以实施例1制备的原儿茶醛和镍铁改性的UiO-66-NH2的杂化材料进行表征及抗菌试验。
1、体外抗菌实验
(1)测定原儿茶醛和镍铁改性的UiO-66-NH2的杂化材料对大肠杆菌的MBC值MBC值为最小杀菌浓度，指能够杀灭培养基内细菌(即杀灭99.9％供试微生物)的最小浓度。将250μL的不同浓度样品与250μL 2×106CFU/mL细菌悬浮液依次加入到5mL离心管中，使得样品的终浓度为2、1、0.5、0.25mg/mL，恒温震荡培养后取出10μL各样品于9990μL LB培养液中进行稀释，取100μL各样品最终稀释液于LB固体培养基中进行铺板，37℃恒温培养24h后，记录平板上的菌落数量，平板菌落低于5个的最低浓度即为MBC值。
(2)测定原儿茶醛和镍铁改性的UiO-66-NH2的杂化材料对大肠杆菌的MIC值MIC值为最小抑菌浓度，指在体外培养细菌18至24h后能抑制培养基内病原菌生长的最小药物浓度。将100μL不同浓度(16mg/mL～0.05mg/mL)的样品后和100μL的106CFU/mL细菌悬浮液在无菌96孔板中混合并进行梯度稀释。对照组为200μL的纯LB培养液和200μL的0.5×106CFU/mL的细菌悬浮液。将96孔板恒温震荡培养12h后通过测定肉眼判断和OD600值确认没有可见浑浊度的样品的最低浓度，即为鱼精蛋白和镍铁改性的UiO-66-NH2的杂化材料的MIC值。
表1各组对金黄色葡萄球菌(S.aureus)和大肠杆菌(E.coli)的MIC与MBC值
| UiO-66-NH2 | Ni@Fe/UiO-66-NH2 | DIH/Ni@Fe/UiO-66-NH2 | |
| MIC(E.coli)(mg/mL) | 2.0 | 1.5 | 1.0 |
| MBC(E.coli)(mg/mL) | 4.0 | 3.0 | 2.0 |
| MIC(S.aureus)(mg/mL) | 8.0 | 6.0 | 1.25 |
| MBC(S.aureus)(mg/mL) | 16.0 | 12.0 | 2.5 |
试验结果：
如表1所示，原儿茶醛和镍铁改性的UiO-66-NH2的杂化材料与未改性前及未与原儿茶醛杂化前的材料的抗菌性能具有明显提升，显著降低了对大肠杆菌和金黄色葡萄球菌的抑制所需浓度，展现出杂化材料的优异协同抗菌特性。
2、MRSA抑制实验
将培养至对数期的MRSA菌悬液与原儿茶醛和镍铁改性的UiO-66-NH2混合培养3h。孵育后，将悬浮液用生理盐水稀释，取100μL稀释液涂布到LB固体培养基上培养过夜，进行菌落计数。同时设置暗对照，空白对照与只加菌液的阴性对照。
试验结果：
如图1所示，在相同浓度下使用三种材料进行对耐甲氧西林金黄色葡萄球菌抗菌性能的测试，原儿茶醛和镍铁改性的UiO-66-NH2的杂化材料表现出了对MRSA极大的抑制作用，能够降低耐药菌所带来了耐药性的危害，为治疗耐药菌提供了新的思路。
3、细胞相容性实验
利用细胞毒性检测(MTT)研究了不同浓度的原儿茶醛和镍铁改性的UiO-66-NH2对人克隆结肠腺癌细胞(Caco2)的毒性。
为了评估细胞毒性，首先将人克隆结肠腺癌细胞(Caco2)用DMEM培养基在96孔板上培养24h，并在添加不同剂量原儿茶醛和镍铁改性的UiO-66-NH2(0-250μg/mL)后继续培养24h。用MTT法测定，用吸光度结果(A490)定量细胞活力。
试验结果：
如图2所示，原儿茶醛和镍铁改性的UiO-66-NH2的杂化材料在设置组的浓度梯度中都展现出了良好的细胞相容性，细胞存活率均在80％以上，表明原儿茶醛和镍铁改性的UiO-66-NH2的杂化材料的细胞毒性较低，具有良好的生物安全性能。
3、吸附性测试
首先在反应管中加入50mL初始浓度为30mg/L的氨苄青霉素钠溶液，称取0.06g各实施例中制备的金属有机框架材料加入到上述100mL溶液中，30min后测定对氨苄青霉素钠溶液的吸附率；随后通过紫外分光光度计测试溶液中剩余氨苄青霉素钠的浓度，计算样品对氨苄青霉素钠溶液的降解率(％)。
表2各组吸附性实验结果
| UiO-66-NH2 | Ni@Fe/UiO-66-NH2 | DIH/Ni@Fe/UiO-66-NH2 | |
| 吸附率(％)(30min) | 93.0 | 97.0 | 98.8 |
试验结果：
如表2所示，原儿茶醛和镍铁改性的UiO-66-NH2的杂化材料表现出比改性前更强的吸附效率，表明原儿茶醛和镍铁改性的UiO-66-NH2具有良好的催化性能。
上述说明并非对本发明的限制，本发明也并不限于上述举例。本技术领域的普通技术人员在本发明的实质范围内，做出的变化、改型、添加或替换，也应属于本发明的保护范围。
Claims (10)
1.一种原儿茶醛与镍铁改性的UiO-66-NH2的杂化材料的制备方法，其特征在于，所述制备方法包括如下步骤：
步骤(1)、UiO-66-NH2的制备
将氯化锆、2-氨基对苯二甲酸与对苯二甲酸分散至N,N-二甲基甲酰胺DMF中，搅拌下加入去离子水，加热反应一段时间；冷却至室温后，离心收集固体产物，置于无水乙醇中一段时间，取出烘干后即得UiO-66-NH2；所述氯化锆、2-氨基对苯二甲酸与对苯二甲酸的质量比为5：1：(2.5～2.7)；
步骤(2)、镍铁改性的UiO-66-NH2杂化材料的制备
将铁盐、镍盐溶于无水甲醇中，加入步骤(1)所得UiO-66-NH2，分散均匀，常温搅拌12～24h，然后在惰性气氛中煅烧，得到所述镍铁改性的UiO-66-NH2杂化材料；UiO-66-NH2、铁盐中的铁离子、镍盐中的镍离子与无水甲醇的摩尔比为1：(1.5～2)：(1.5～2)：(3000～4000)；
步骤(3)、原儿茶醛与镍铁改性的UiO-66-NH2的杂化材料的制备
将原儿茶醛分散至水中，加入步骤(2)所得镍铁改性的UiO-66-NH2的杂化材料进行浸渍，静置后洗涤干燥得到所述原儿茶醛与镍铁改性UiO-66-NH2的杂化材料。
2.根据权利要求1所述的制备方法，其特征在于，步骤(1)中加热时间为22～24h，加热温度为118～120℃。
3.根据权利要求1所述的制备方法，其特征在于，步骤(1)中置于乙醇中22～24h。
4.根据权利要求1所述的制备方法，其特征在于，步骤(2)中水热反应的时间为24h，水热反应的温度为120℃。
5.根据权利要求1所述的制备方法，其特征在于，步骤(2)中铁盐选自二价铁盐、三价铁盐中一种或两种；所述二价铁盐为氯化亚铁、硝酸亚铁、硫酸亚铁、醋酸亚铁中任意一种或几种；所述三价铁盐为氯化铁、硝酸铁、硫酸铁、醋酸铁中一种或几种。
6.根据权利要求1所述的制备方法，其特征在于，步骤(2)中镍盐选自硝酸镍、氯化镍中一种或两种。
7.根据权利要求1所述的制备方法，其特征在于，步骤(2)中煅烧温度为600～900℃，升温速率为1～10℃/min，煅烧时间为4～16h。
8.根据权利要求1所述的制备方法，其特征在于，步骤(3)中浸渍的时间为4～40h。
9.一种原儿茶醛与镍铁改性的UiO-66-NH2的杂化材料，其特征在于，采用权利要求1-8任一项所述方法制备得到。
10.权利要求9所述杂化材料作为抗菌材料或催化剂的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311088924.7A CN117137891A (zh) | 2023-08-28 | 2023-08-28 | 一种原儿茶醛与镍铁改性的UiO-66-NH2的杂化材料及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311088924.7A CN117137891A (zh) | 2023-08-28 | 2023-08-28 | 一种原儿茶醛与镍铁改性的UiO-66-NH2的杂化材料及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117137891A true CN117137891A (zh) | 2023-12-01 |
Family
ID=88905509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311088924.7A Pending CN117137891A (zh) | 2023-08-28 | 2023-08-28 | 一种原儿茶醛与镍铁改性的UiO-66-NH2的杂化材料及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117137891A (zh) |
-
2023
- 2023-08-28 CN CN202311088924.7A patent/CN117137891A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20130171228A1 (en) | Anti-microbial metal organic framework | |
| Galkina et al. | Antibacterial and photochemical properties of cellulose nanofiber–titania nanocomposites loaded with two different types of antibiotic medicines | |
| Cardoso et al. | Antibacterial activity of silver camphorimine coordination polymers | |
| Agnihotri et al. | Synthesis and antimicrobial activity of aminoglycoside-conjugated silica nanoparticles against clinical and resistant bacteria | |
| Rauf et al. | Synthesis, structure and antibacterial activity of a copper (II) coordination polymer based on thiophene-2, 5-dicarboxylate ligand | |
| Efthimiadou et al. | Mononuclear metal complexes of the second-generation quinolone antibacterial agent enrofloxacin: Synthesis, structure, antibacterial activity and interaction with DNA | |
| Chandrakanth et al. | Potential bactericidal effect of silver nanoparticles synthesised from Enterococcus species | |
| Nakhaei et al. | Antibacterial activity of three zinc-terephthalate MOFs and its relation to their structural features | |
| da Silva et al. | Visible light plasmon excitation of silver nanoparticles against antibiotic-resistant Pseudomonas aeruginosa | |
| Edeler et al. | SBA-15 mesoporous silica particles loaded with cisplatin induce senescence in B16F10 cells | |
| Alshima'a et al. | Bis 4, 5-diazafluoren-9-one silver (I) nitrate: Synthesis, X-ray structures, solution chemistry, hydrogel loading, DNA coupling and anti-bacterial screening | |
| Zafar et al. | Green synthesis of ciprofloxacin-loaded cerium oxide/chitosan nanocarrier and its activity against MRSA-induced mastitis | |
| Díaz-García et al. | Copper-functionalized nanostructured silica-based systems: Study of the antimicrobial applications and ROS generation against gram positive and gram negative bacteria | |
| Hajibabaei et al. | Synthesis, characterization and antibacterial activity of imidazole-functionalized Ag/MIL-101 (Cr) | |
| El-Gamel | Coordination behaviour and biopotency of metal NN salen complexes | |
| Yang et al. | Multifunctional nanoreactors with nutrient consumption and ROS generation capabilities for antibacterial and skin repair | |
| CN114246870A (zh) | MIL-101(Fe)-T705及其制备方法和应用 | |
| CN117137891A (zh) | 一种原儿茶醛与镍铁改性的UiO-66-NH2的杂化材料及其制备方法和应用 | |
| Ramos et al. | Linezolid@ MOF-74 as a host–guest system with antimicrobial activity | |
| CN117137892A (zh) | 一种香兰素与镍铁改性的UiO-66-NH2的杂化材料及其制备方法和应用 | |
| CN117210020A (zh) | 一种鱼精蛋白与镍铁改性的UiO-66-NH2的杂化材料及其制备方法和应用 | |
| He et al. | Green Synthesis of MOF-Mediated pH-Sensitive Nanomaterial AgNPs@ ZIF-8 and Its Application in Improving the Antibacterial Performance of AgNPs | |
| Ameen et al. | Excellent antimicrobial performances of Cu (II) metal organic framework@ Fe3O4 fused cubic particles | |
| Charan et al. | Antiviral activity of antimony and arsenic oxides | |
| Lu et al. | A bio-platform TCN@ HKUST-1 with admirable biocompatibility was applied to the antibacterial field |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |